Gubra
566 DKK -5.98%HC Andersen Capital receives payment from Gubra for a DigitalIR/Corporate Visibility agreement. See disclaimer.
14 investors are following this company
Gubra is a pharmaceutical company. The company's operations are focused on the early stages of drug development. They mainly conduct research and development in the field of metabolic and fibrotic diseases. The company's product portfolio includes several brands and pharmaceuticals, and operations are conducted on a global level, with the largest presence in North America and the Nordics. The head office is located in Hørsholm, Denmark.
Revenue
205.01M
EBIT %
-23.25 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Copenhagen
GUBRA
Daily low / high price
560 / 616
DKK
Market cap
9.25B DKK
Turnover
83.68M DKK
Volume
145K
Latest research
Latest videos
Financial calendar
Interim report
23.08.2024
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Niels Vrang | 30.6 % | 30.6 % |
Jacob Jelsing | 27.5 % | 27.5 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Dagens aktienyheder 02/07: Gubra, BioPorto A/S, Asetek og ExpreS2ion Biotechnologies
Gubra: Share price moves to all-time high as another partner project enters phase 1
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools